NEMAR copy of ds007865
You're viewing the NEMAR copy at v1.0.0.
Each OpenNeuro pull is a NEMAR major bump
(vN.0.0); intermediate versions are NEMAR-side fixes.
Placebo Neuroepo multisession Phase II and III
A randomized, placebo-controlled clinical trial investigating the neuroprotective and neuromodulatory effects of intranasal NeuroEPO (erythropoietin) in Parkinson's disease patients. The dataset comprises multisession EEG recordings and clinical assessments collected at two timepoints: baseline (pre-intervention) and 9 months post-intervention, with participants stratified by treatment exposure (NeuroEPO vs. placebo). Motor function was evaluated using the MDS-UPDRS III scale, and EEG source activity was examined as a potential mediator of treatment-related cognitive and functional outcomes.
AI-generated description, may include mistakesLoading demographics…
Coming soon. Per-file data-quality summaries are precomputed by the NEMAR processing pipeline. The static aggregate is on the way — tracked at nemar-cli#511.